The Canadian division of Taro Pharmaceuticals (NYSE:TARO) has announced a voluntary Type 1 recall of six lots of Taro-zoledronic Acid Injection. Type 1 recalls, according to Health Canada, refer to products that could cause serious adverse health consequences or death. It corresponds to Class 1 recalls from the FDA. Taro Pharmaceutical‘s consumer-level recall covers 5 mg/100…